{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-013467","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2025-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.970789+00:00","generated_at":"2026-05-26T21:09:24.298085+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"AbbVie appoints CEO Robert Michael as Chairman, Gonzalez to retire July 1, 2025","bullets":["CEO Robert A. Michael unanimously elected Chairman, effective July 1, 2025.","Chairman Richard A. Gonzalez retires from board effective July 1, 2025; served as Chairman since AbbVie's 2013 formation.","Director Glenn F. Tilton also retires from board effective July 1, 2025; lead independent director from 2013 to 2024.","Michael continues as CEO and assumes additional role of Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-013467","json":"https://secwatch.observer/filing/0001104659-25-013467.json","markdown":"https://secwatch.observer/filing/0001104659-25-013467.md","text":"https://secwatch.observer/filing/0001104659-25-013467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000110465925013467/0001104659-25-013467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000110465925013467/tm256372d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T21:09:24.298085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a19489c8c","claim":"Glenn F. Tilton departed as Director at AbbVie Inc..","evidence_excerpt":"Glenn F. Tilton informed the Company of his decision to retire as a director, effective July 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465925013467/0001104659-25-013467-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3f866dde00","claim":"Richard A. Gonzalez departed as Chairman at AbbVie Inc..","evidence_excerpt":"Mr. Gonzalez, who has served as Chairman since the Company’s formation in 2013, will retire from the Board, effective July 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465925013467/0001104659-25-013467-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Chairman"}],"fact_type":"executive_change"},{"claim_id":"523a1aedb8","claim":"Robert A. Michael was elected as Chairman of the Board at AbbVie Inc..","evidence_excerpt":"On February 13, 2025, the Board of Directors (the “Board”) of AbbVie Inc. (the “Company”) unanimously elected Robert A. Michael to succeed Richard A. Gonzalez as the Company’s Chairman, effective July 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465925013467/0001104659-25-013467-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}